Aldeyra Therapeutics Holds Annual Meeting with Key Votes

Aldeyra Therapeutics ( (ALDX) ) just unveiled an update.

At the Aldeyra Therapeutics annual meeting held on June 10, 2025, stockholders voted on several key proposals. These included the election of three directors to serve until 2028, the ratification of BDO USA, P.C. as the independent public accounting firm for 2025, and an advisory vote approving executive compensation. The meeting saw a significant participation rate with approximately 76.2% of shares represented, indicating strong shareholder engagement.

The most recent analyst rating on (ALDX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aldeyra Therapeutics stock, see the ALDX Stock Forecast page.

Spark’s Take on ALDX Stock

According to Spark, TipRanks’ AI Analyst, ALDX is a Underperform.

Aldeyra Therapeutics faces substantial financial and regulatory challenges, reflected in its low overall score. The lack of revenue and continuous losses are significant risks, compounded by negative technical indicators. The recent FDA response letter adds further uncertainty. However, strong cash reserves and a strategic board appointment provide some potential for recovery if product development succeeds.

To see Spark’s full report on ALDX stock, click here.

More about Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies for immune-mediated diseases. The company is engaged in creating innovative treatments aimed at improving patient outcomes in various therapeutic areas.

Average Trading Volume: 1,797,344

Technical Sentiment Signal: Sell

Current Market Cap: $160.8M

For detailed information about ALDX stock, go to TipRanks’ Stock Analysis page.